

PROLIGHT ANNOUNCES TIMETABLE FOR SHARE REVERSE SPLIT

The extraordinary general meeting in Prolight Diagnostics AB (publ) on 19 November 2025, resolved on a reverse share split of 1:100, whereby one hundred (100) existing shares will be consolidated into one (1) new share. The extraordinary general meeting authorised the board of directors to determine the record date for the reverse share split. The board of directors has, pursuant to the authorisation, resolved that the record date for the reverse share split shall be 11 December 2025.

Timeline for the reverse share split:

9 December 2025	The last day of trading in Prolight's shares before the reverse share split.
10 December 2025	First day of trading in Prolight's shares following the reverse share split. From this date, the share price will reflect the effect of the reverse share split.
11 December 2025	Record date for the reverse share split

Shareholders are not required to take any action to participate in the reverse share split. Following the reverse share split, Prolight's shares will change ISIN code. The new ISIN code SE0027099656 will apply from 10 December 2025.

A shareholder who on the record date does not hold a number of shares that is evenly divisible by 100 will receive, from Mangold Fondkommission AB (the guarantor), free of charge such number of shares (1–99 shares) that the shareholder's holding, after addition of provided shares, is evenly divisible by 100 (so-called rounding up). The provision of such equalization shares will be provided through Euroclear Sweden AB, without requiring any further action from shareholders.

Following the reverse share split, the number of shares in the company will amount to 12,044,782, which represents a quota value of SEK 10 per share.

For further information, please contact:

Ulf Bladin, CEO

E-mail: info@prolightdx.com

Phone: +46 73 582 39 87

Company website: www.prolightdx.com

About Us

Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.

The company's share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.

Attachments

Prolight announces timetable for share reverse split